WT1 antigen peptide conjugate vaccine

Patent metadata

Field	Value
Publication number	US-9248173-B2
Application number	US-201514706772-A
Country	US
Kind code	B2
Filing date	May 7, 2015
Priority date	Mar 29, 2013
Publication date	Feb 2, 2016
Grant date	Feb 2, 2016

Abstract

A compound represented by the formula (1):

wherein X a and Y a are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R 1 is a hydrogen atom, a group represented by the formula (2):

wherein X b and Y b are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

First claim

The invention claimed is:

1. A method of treating WT1 positive cancer, comprising:
administering a therapeutically effective amount of a pharmaceutical composition to a WT1 positive cancer patient in need thereof, the pharmaceutical composition comprising
a compound selected from the group consisting of

wherein the bond between CR is a bond between the carbonyl group of C and the N-terminal amino group of R, and the bond between C and C is a disulfide bond,

or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and
a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRK.
(SEQ ID NO: 22) 

4. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and
a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRKHTG.
(SEQ ID NO: 24)

5. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and
a peptide consisting of an amino acid sequence:

CWAPVLDFAPPGASAYGSL.
(SEQ ID NO: 242)

6. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and
a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSLC.
(SEQ ID NO: 243)

7. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and
a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSL.
(SEQ ID NO: 244)

8. The method of claim 1 , wherein the WT1 positive cancer is one of leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colorectal cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, urinary bladder cancer, prostate cancer, uterine cancer, cervical cancer, ovarian cancer, and brain tumor.

9. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRK.
(SEQ ID NO: 22) 

10. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRKHTG.
(SEQ ID NO: 24)

11. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CWAPVLDFAPPGASAYGSL.
(SEQ ID NO: 242)

12. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSLC.
(SEQ ID NO: 243)

13. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSL.
(SEQ ID NO: 244)

14. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (4):

or a pharmaceutically acceptable salt thereof.

15. A method of inducing cytotoxic T cells against WT1 positive cancer, comprising:
administering an effective amount of a pharmaceutical composition to a subject, the pharmaceutical composition comprising
a compound selected from the group consisting of

wherein the bond between CR is a bond between the carbonyl group of C and the N-terminal amino group of R, and the bond between C and C is a disulfide bond,

or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier.

16. The method of claim 15 , wherein the pharmaceutical composition comprises the compound having the formula (5):

or a pharmaceutically acceptable salt

Assignees

• Sumitomo Dainippon Pharma Co Ltd
• Int Inst Cancer Immunology Inc

Inventors

• Li Chiang Jia
• Ban Hitoshi
• Nishio Yukihiro
• Goto Masashi
• Nishihara Toshio
• Takanashi Yosuke

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• A61K47/646

  the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title